Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COMBOGESIC IV vs ALEVE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of acetaminophen (paracetamol) and ibuprofen. Acetaminophen: Weak COX inhibition in CNS, analgesic and antipyretic. Ibuprofen: Non-selective COX-1/COX-2 inhibition, anti-inflammatory, analgesic, antipyretic.
Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to decreased inflammation, pain, and fever.
Management of mild to moderate pain,Reduction of fever (acetaminophen component),Off-label: Acute pain relief in various settings
Rheumatoid arthritis,Osteoarthritis,Ankylosing spondylitis,Juvenile arthritis,Tendonitis,Bursitis,Acute gout,Primary dysmenorrhea,Mild to moderate pain,Fever
1 vial (1000 mg paracetamol + 60 mg codeine phosphate) IV infusion over 15 minutes, every 4-6 hours as needed, max 4 vials per day.
220 mg orally every 8 to 12 hours as needed; maximum 660 mg per day.
Paracetamol: 1.5-3 hours; tramadol: 6 hours (active metabolite M1: 7-9 hours). Clinical context: Extended half-life in hepatic impairment (cirrhosis) and elderly; requires dose adjustment.
Terminal elimination half-life is 12-17 hours; allows twice-daily dosing for steady-state concentrations.
Acetaminophen: Hepatic via conjugation (glucuronidation, sulfation) and CYP2E1 (minor) to reactive metabolite NAPQI. Ibuprofen: Hepatic via CYP2C9 and CYP2C8 to inactive metabolites.
Naproxen is extensively metabolized in the liver primarily via CYP2C9 to 6-O-desmethyl naproxen, and less than 5% is excreted unchanged in urine.
Renal: 90% as glucuronide conjugates and unchanged drug for paracetamol; biliary: 10% for paracetamol. For tramadol: renal 90% (unchanged and metabolites), fecal 10%.
Renal (95% as unchanged drug and metabolites); biliary/fecal (5%)
Paracetamol: 10-25% bound to albumin; tramadol: 20% bound to albumin; active metabolite M1: negligible binding.
>99% bound to albumin; saturable at high concentrations.
Paracetamol: 0.9 L/kg; tramadol: 2.7 L/kg (wide distribution into tissues). Clinical meaning: High Vd for tramadol indicates extensive tissue distribution.
0.16 L/kg; indicates distribution primarily in extracellular fluid.
IV: 100% for both components. Oral: Paracetamol 85-90%; tramadol 75% (first-pass metabolism). Not applicable for IM/SC routes.
Oral: ~95%; immediate-release formulation.
e GFR 30-50 m L/min: administer every 6 hours; e GFR <30 m L/min: not recommended; dialysis: contraindicated.
GFR 30-59 m L/min: reduce dose and avoid long-term use; GFR <30 m L/min: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval; Child-Pugh C: contraindicated.
Child-Pugh class A: no adjustment; Child-Pugh class B or C: avoid use.
Children >12 years and ≥50 kg: same as adult dose; <12 years or <50 kg: not recommended due to codeine; use alternative analgesic.
2-12 years: 2.5-5 mg/kg/dose orally every 8-12 hours; maximum 10 mg/kg/day. 12 years and older: same as adult.
Initiate at lowest effective dose; monitor for respiratory depression and hypotension; consider reduced dose or extended interval due to age-related clearance decline.
Initiate at lowest effective dose (220 mg every 12 hours); maximum 440 mg per day; monitor renal function and GI bleeding risk.
Risk of severe hepatic injury with acetaminophen; do not exceed maximum daily dose (4 g/day).
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors may be at greater risk. Naproxen is contraindicated for treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease or GI bleeding are at greater risk.
Hepatotoxicity (acetaminophen overdose), GI bleeding/ulceration (ibuprofen), renal impairment, cardiovascular thrombotic events (ibuprofen), anaphylactic reactions, masking of infection signs.
Cardiovascular thrombotic events,Gastrointestinal bleeding, ulceration, and perforation,Hypertension,Heart failure and edema,Renal toxicity,Anaphylactoid reactions,Serious skin reactions (e.g., Stevens-Johnson syndrome),Hematologic toxicity (inhibition of platelet aggregation),Exacerbation of asthma,Hepatic effects,Pregnancy: avoid during third trimester
Hypersensitivity to any component, active GI bleeding, severe hepatic impairment, severe renal impairment (Cr Cl <30 m L/min), history of asthma/urticaria with NSAIDs, perioperative pain in CABG surgery.
History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Peri-operative pain in the setting of CABG surgery,Advanced renal disease,History of gastrointestinal bleeding or perforation related to previous NSAID therapy,Active gastrointestinal bleed
Concurrent food intake does not affect IV administration. However, patients should avoid alcohol consumption due to increased risk of hepatotoxicity from paracetamol and gastrointestinal bleeding from ibuprofen. No other specific food interactions are known.
Avoid concurrent use of alcohol as it increases GI bleeding risk. No specific food restrictions; taking with food or milk may reduce dyspepsia. High potassium foods (e.g., bananas, spinach) may increase hyperkalemia risk in patients with renal impairment.
First trimester: Avoid combination acetaminophen/NSAIDs due to potential cardiovascular and neural tube defects with NSAIDs; acetaminophen considered relatively safe but limit use. Second trimester: NSAIDs associated with oligohydramnios and fetal renal effects; acetaminophen safe at therapeutic doses. Third trimester: NSAIDs contraindicated due to risk of premature ductus arteriosus closure, oligohydramnios, and neonatal renal impairment; acetaminophen preferred.
First trimester: Risk of spontaneous abortion and cardiac defects (odds ratio 1.86 for NSAIDs). Second trimester: Possible fetal renal dysfunction and oligohydramnios; ductus arteriosus premature closure risk begins. Third trimester: High risk of premature closure of ductus arteriosus, oligohydramnios, necrotizing enterocolitis, intracranial hemorrhage, and renal impairment; avoid after 30 weeks.
Acetaminophen: Low transfer into breast milk, M/P ratio 0.91-1.42; considered compatible with breastfeeding. Ibuprofen (if applicable, assuming NSAID component): M/P ratio 0.01-0.06, very low levels; considered compatible. Avoid NSAIDs if infant has thrombocytopenia or renal impairment. Monitor infant for rash, drowsiness, or gastrointestinal effects.
Excreted in breast milk in low concentrations (M/P ratio ~0.12); relative infant dose <1% of maternal weight-adjusted dose. Compatible with breastfeeding; monitor infant for potential adverse effects (gastrointestinal upset, rash) at higher doses.
Acetaminophen: No dose adjustment needed; use lowest effective dose. NSAID component: Avoid in third trimester; if necessary in earlier trimesters, use lowest effective dose for shortest duration. Pharmacokinetic changes (increased plasma volume, enhanced clearance) may require higher acetaminophen dosing but not standardly adjusted; monitor effect.
No specific pharmacokinetic-based dose adjustments; however, use lowest effective dose for shortest duration, especially after 20 weeks. Avoid use after 30 weeks gestation due to fetal risks. Increased volume of distribution may reduce serum concentrations but no dose adjustment recommended.
COMBOGESIC IV is a fixed-dose combination of paracetamol (acetaminophen) 1000 mg and ibuprofen 300 mg per 100 m L solution. Administer only as a single intravenous infusion over 15 minutes. Do not administer if the solution contains particulates or is discolored. Avoid use in patients with severe hepatic impairment (Child-Pugh C), severe renal impairment (e GFR <30 m L/min/1.73m²), active peptic ulcer disease, or history of aspirin allergy. Monitor for signs of hepatotoxicity (paracetamol) and renal toxicity (ibuprofen). Contraindicated in patients with severe heart failure (NYHA III/IV) or preoperative CABG surgery. Use lowest effective dose for shortest duration. Not recommended for patients <18 years due to lack of safety data. Contains ibuprofen; risk of serious GI adverse events including bleeding, ulceration, and perforation, especially in elderly. Do not exceed 4 doses (4000 mg paracetamol/1200 mg ibuprofen) per day. Concomitant use of other NSAIDs or paracetamol-containing products is contraindicated.
ALEVE (naproxen sodium) is a nonsteroidal anti-inflammatory drug (NSAID) with a longer half-life (12-17 hours) allowing twice-daily dosing. It carries a boxed warning for cardiovascular and gastrointestinal risk. Use lowest effective dose for shortest duration. Contraindicated in patients with aspirin allergy, perioperative pain in CABG surgery, and significant renal impairment. Monitor renal function in elderly, volume-depleted patients, and those on ACE inhibitors or diuretics.
This medication is given intravenously and is not for self-administration.,Inform your healthcare provider if you have a history of liver or kidney disease, stomach ulcers, bleeding disorders, heart disease, high blood pressure, or asthma.,Avoid taking any additional acetaminophen (paracetamol) or NSAIDs (e.g., ibuprofen, naproxen) while receiving this medication.,Report any signs of allergic reaction (rash, itching, swelling, difficulty breathing), stomach pain, black or bloody stools, vomiting blood, unusual bruising or bleeding, yellowing of skin or eyes, dark urine, or severe fatigue.,Do not consume alcohol while being treated with this medication; alcohol increases the risk of liver damage and stomach bleeding.,This medication may cause dizziness or drowsiness; avoid driving or operating machinery if affected.,Tell your doctor about all medications you are taking, including prescription, over-the-counter, and herbal products, especially blood thinners (warfarin, aspirin), diuretics, lithium, methotrexate, and ACE inhibitors.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss the risks with your healthcare provider.
Take with food or milk to reduce GI upset.,Do not exceed 2 tablets (440 mg) in 24 hours unless directed by a doctor.,Avoid alcohol consumption to lower risk of GI bleeding.,Stop use and seek medical help if you experience chest pain, weakness, slurred speech, or signs of stomach bleeding (black/tarry stools, vomit that looks like coffee grounds).,Do not use with other NSAIDs (e.g., ibuprofen, aspirin) unless prescribed.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COMBOGESIC IV vs ALEVE, answered by our medical review team.
COMBOGESIC IV is a Analgesic Combination (Opioid + Non-Opioid) that works by Combination of acetaminophen (paracetamol) and ibuprofen. Acetaminophen: Weak COX inhibition in CNS, analgesic and antipyretic. Ibuprofen: Non-selective COX-1/COX-2 inhibition, anti-inflammatory, analgesic, antipyretic.. ALEVE is a Nonsteroidal Anti-inflammatory Drug (NSAID) that works by Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to decreased inflammation, pain, and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COMBOGESIC IV and ALEVE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COMBOGESIC IV is: 1 vial (1000 mg paracetamol + 60 mg codeine phosphate) IV infusion over 15 minutes, every 4-6 hours as needed, max 4 vials per day.. The standard adult dose of ALEVE is: 220 mg orally every 8 to 12 hours as needed; maximum 660 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COMBOGESIC IV and ALEVE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COMBOGESIC IV is classified as Category C. First trimester: Avoid combination acetaminophen/NSAIDs due to potential cardiovascular and neural tube defects with NSAIDs; acetaminophen considered relatively safe but limit use.. ALEVE is classified as Category C. First trimester: Risk of spontaneous abortion and cardiac defects (odds ratio 1.86 for NSAIDs). Second trimester: Possible fetal renal dysfunction and oligohydramnios; ductus arter. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.